News & Updates

May 17, 2020

Sage’s client, Cancer Prevention Pharmaceuticals (“CPP”; www.canprevent.com),is a late clinical stage company developing a unique, oral, fixed dose combination drug (CPP-1X/sul) to treat Familial Adenomatous Polyposis (FAP), an inherited disorder characterized by cancer of the large intestine (colon) and rectum. People with the classic type of FAP may beg...

April 22, 2020

The Sage Group is pleased to announce it has been appointed to represent a product from Squarex LLC, SQX770, the only product which prevents cold sores (herpes labialis), meaning it significantly reduces the number of cold sore flareups in a given period and reduces the severity when there are flareups. Please see the attached nonconfidential presentation...

March 3, 2020

London, England and New York, February 17 2020 - The Sage Group Inc. today announced that Dr. Christine T. Fischette will join the firm as an Executive Director.  “We are delighted that Chris has decided to join Sage. Chris will bring her wide-ranging expertise with healthcare and bioscience clients to The Sage Group. Chris has a prestigious career in the...

February 15, 2020

London, England, Shanghai, China, and New York, February 17 2020 - The Sage Group, Inc. today announced that they have partnered with T-Capital to extend their global reach into the People’s Republic of China. The principal objective is to broaden their portfolio of strategic licensing and partnering services for their healthcare clients in pharmaceutical...

February 10, 2020

SAN DIEGO & PENNINGTON, N.J.--(BUSINESS WIRE)-- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, following shareholder approval, the proposed strategic investment by and partnership (the “CGP/Sirtex Transaction”) with Grand Decade Development...

February 5, 2020

London, England and New York, February 5 2020 - The Sage Group, Inc. today announced that Dr. Clarissa Ceruti will join the firm as an Executive Director. “We are very pleased that Clarissa has decided to join Sage. She will significantly expand our capability and expertise in serving the strategic transactional needs of our clients. Also, since Clarissa...

January 1, 2020

Sage Group is working with medac GmbH who have developed Trecondi®, (Treosulfan), as a superior drug in conjunction with fludarabine prior to allogeneic hematopoetic stem cell transplantation (alloHSCT) in patients suffering from AML or MDS.

medac completed a European clinical study of 570 patients (NCT 00822393). This randomized Phase III trial was design...

December 2, 2019

BioHit Healthcare has developed and gained approval in Europe for the Acetium® lozenge. This binds cigarette smoke-derived acetaldehyde in the saliva, thus reducing the known effects of acetaldehyde in maintaining smoking dependence. Regular use of the Acetium® lozenge during smoking increased the likelihood of smoking cessation 1.5-fold compared with pla...

Please reload